The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by hemolytic anemia, bone marrow failure and thrombosis, and is associated with high healthcare burden. We evaluated the cost-effectiveness of pegcetacoplan, a proximal complement-3 inhibitor (C3i), compared with the C5i, eculizumab and ravulizumab, in complement treatment-naive adults with PNH, from the US healthcare payer perspective. A cost-effectiveness model based on a Markov cohort structure evaluated lifetime (55-year) PNH costs and outcomes.

Validation of the FINE-CKD model for future health technology assessments for finerenone in patients with chronic kidney disease and type 2 diabetes.

Background: The FINE-CKD model was developed to estimate the cost-effectiveness of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).

Objective: To perform internal and external validation by comparing the model estimates with trial results and outcomes from other models.

Methods: Incidence rates from trials were compared with the model predictions.

Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe.

Background And Objective: A cost-minimization model was developed to compare recombinant factor VIII Fc (rFVIIIFc) and emicizumab as prophylaxis for hemophilia A without inhibitors.

Methods: The model was based on 100 patients from the healthcare payer perspective in the UK, France, Italy, Spain, and Germany (5-year time horizon). Costs included: drug acquisition; emicizumab wastage by bodyweight (manufacturer's dosing recommendations); and additional FVIII for breakthrough bleeds.

Antimicrobial and anti-biofilm activity of thiourea derivatives incorporating a 2-aminothiazole scaffold.

A series of new thiourea derivatives of 1,3-thiazole have been synthesized. All obtained compounds were tested in vitro against a number of microorganisms, including Gram-positive cocci, Gram-negative rods and Candida albicans. Compounds were also tested for their in vitro tuberculostatic activity against the Mycobacterium tuberculosis H37Rv strain, as well as two 'wild' strains isolated from tuberculosis patients.

Poly[[pentaaquasulfato-micro4-(R,R)-tartrato-dicadmium(II)] trihydrate].

The asymmetric unit in the title compound, {[Cd(2)(C(4)H(4)O(6))(SO(4))(H(2)O)(5)].3H(2)O}(n), is composed of two cadmium cations, one (R,R)-tartrate and one sulfate anion, five aqua ligands and three solvent water molecules. One of the cadmium ions is coordinated in an octahedral environment, whereas the second is surrounded by seven O atoms in a pentagonal-bipyramidal geometry.